First-in-human administration of [ 161 Tb]Tb-SibuDAB and comparative dosimetry with standard [ 177 Lu]Lu-PSMA-I&T as part of the PROGNOSTICS phase Ia study.

Competing Interests: Declarations. Ethics approval: Aproved by the Ethics Committee of Northwest and Central Switzerland (06.11.2023; 2023 − 01868). Consent to participate: Informed consent was obtained from the patient before the inclusion into the study. The patient gave written informed consend to anonymously use his clinical and imaging data for publication. Competing interests: Patent applications on PSMA ligands with albumin-binding entities have been filed by ITM Medical Isotopes GmbH, Germany. CM and RS are listed as co-inventors on the patent application. PB is a co-founder of Theravision AB.